UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis

Clinical pharmacokinetics, 2019-01, Vol.58 (1), p.15-37

2019

Volltextzugriff (PDF)

Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial

Scandinavian journal of gastroenterology, 2021-02, Vol.56 (2), p.145-154

2021

Volltextzugriff (PDF)

Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation

British journal of clinical pharmacology, 2019-07, Vol.85 (7), p.1544-1551

2019

Volltextzugriff (PDF)

Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?

Expert review of clinical pharmacology, 2019-09, Vol.12 (9), p.885-891

2019

Volltextzugriff (PDF)

Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease

Therapeutic drug monitoring, 2018-04, Vol.40 (2), p.202-211

2018

Volltextzugriff (PDF)

Population Pharmacokinetics of Infliximab in Children with Juvenile Idiopathic Arthritis

Therapeutic drug monitoring, 2022-04, Vol.44 (2), p.301-307

2022

Volltextzugriff (PDF)

Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples

Therapeutic drug monitoring, 2020-04, Vol.42 (2), p.289-294

2020

Volltextzugriff (PDF)

Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study

Scandinavian journal of gastroenterology, 2019-06, Vol.54 (6), p.700-706

2019

Volltextzugriff (PDF)

Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial

The Journal of dermatological treatment, 2022-07, Vol.33 (5), p.1-2684

2022

Volltextzugriff (PDF)

Factors Influencing Clearance of Adalimumab in Patients with Crohn's Disease: A Population Pharmacokinetic Study

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S392-S392

2017

Volltextzugriff (PDF)

Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients

Journal of pharmacokinetics and pharmacodynamics, 2019-12, Vol.46 (6), p.543-551

2019

Volltextzugriff (PDF)

Golimumab for moderate to severe ulcerative colitis

Expert review of gastroenterology & hepatology, 2017-05, Vol.11 (5), p.401-406

2017

Volltextzugriff (PDF)

Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease

Gastroenterology (New York, N.Y. 1943), 2019-10, Vol.157 (4), p.997-1006.e6

2019

Volltextzugriff (PDF)

Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease

British journal of clinical pharmacology, 2021-01, Vol.87 (1), p.106-118

2021

Volltextzugriff (PDF)

Tu1822 – Ifx Serum Levels At Trough Do Not Adequately Reflect Exposure in IBD Patients

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-1137-S-1138

2019

Volltextzugriff (PDF)

Effectiveness and safety of switching IBD patients from the originator to the biosimilar infliximab

Cochrane database of systematic reviews, 2018-07, Vol.2018 (7)

2018

Volltextzugriff (PDF)

Mo1856 - Clinical Feasibility of Dried Blood Sampling for Infliximab in IBD-Patients

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-827-S-827

2018

Volltextzugriff (PDF)

Sa1915 - Factors Influencing Clearance of Adalimumab in Patients with Crohn's Disease: A Population Pharmacokinetic Study

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S392-S392

2017

Volltextzugriff (PDF)

832 – Dashboard Driven Dosing of Infliximab is Superior to Conventional Treatment in Inflammatory Bowel Disease: the Precision Randomized Controlled Trial

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-180-S-181

2019

Volltextzugriff (PDF)

Mo1845 - Higher Serum Concentrations of Vedolizumab are Associated with Superior Endoscopic Outcomes in Crohn's Disease: Data from the Love-CD Trial

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-822-S-823

2018

Volltextzugriff (PDF)

Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial

Journal of Dermatological Treatment, 2022, Vol.33 (5), p.2680-2684

2022

Volltextzugriff (PDF)

Ileo-Colon Targeting of the Poorly Water-Soluble Drug Celecoxib Using a pH-Dependent Coating in Combination with Self-Emulsifying Drug Delivery or Solid Dispersion Systems

Pharmaceutics, 2021-05, Vol.13 (5), p.731

2021

Volltextzugriff (PDF)

Consumer-providers of care for adult clients of statutory mental health services

Cochrane database of systematic reviews, 2013-03, Vol.2013 (3), p.CD004807-CD004807

2013

Volltextzugriff (PDF)

Genome-wide association analysis of diverticular disease points towards neuromuscular, connective tissue and epithelial pathomechanisms

Gut, 2019-05, Vol.68 (5), p.854-865

2019

Volltextzugriff (PDF)

A Systematic Review of Consumer-Providers’ Effects on Client Outcomes in Statutory Mental Health Services: The Evidence and the Path Beyond

Journal of the Society for Social Work and Research, 2013, Vol.4 (4), p.333-356

2013

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(15)

Publikationsform

Artikel
(24)
Berichte
(1)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Humans
(10)
Pharmacology & Pharmacy
(9)
Therapeutic Drug Monitoring
(8)
Adult
(7)
Pharmacokinetics
(7)
Inflammatory Bowel Disease
(6)
Colitis, Ulcerative - Drug Therapy
(5)
Female
(5)
Gastroenterology & Hepatology
(5)
Male
(5)
Middle Aged
(5)
Adalimumab
(4)
Antibodies, Monoclonal - Pharmacokinetics
(4)
Antibodies, Monoclonal - Therapeutic Use
(4)
Monoclonal Antibodies
(4)
Aged
(3)
Colon
(3)
Gastroenterology
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis

Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial

Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation

Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?

Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease

Population Pharmacokinetics of Infliximab in Children with Juvenile Idiopathic Arthritis

Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples

Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study

Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial

Factors Influencing Clearance of Adalimumab in Patients with Crohn's Disease: A Population Pharmacokinetic Study

Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients

Golimumab for moderate to severe ulcerative colitis

Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease

Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease

Tu1822 – Ifx Serum Levels At Trough Do Not Adequately Reflect Exposure in IBD Patients

Effectiveness and safety of switching IBD patients from the originator to the biosimilar infliximab

Mo1856 - Clinical Feasibility of Dried Blood Sampling for Infliximab in IBD-Patients

Sa1915 - Factors Influencing Clearance of Adalimumab in Patients with Crohn's Disease: A Population Pharmacokinetic Study

832 – Dashboard Driven Dosing of Infliximab is Superior to Conventional Treatment in Inflammatory Bowel Disease: the Precision Randomized Controlled Trial

Mo1845 - Higher Serum Concentrations of Vedolizumab are Associated with Superior Endoscopic Outcomes in Crohn's Disease: Data from the Love-CD Trial

Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial

Ileo-Colon Targeting of the Poorly Water-Soluble Drug Celecoxib Using a pH-Dependent Coating in Combination with Self-Emulsifying Drug Delivery or Solid Dispersion Systems

Consumer-providers of care for adult clients of statutory mental health services

Genome-wide association analysis of diverticular disease points towards neuromuscular, connective tissue and epithelial pathomechanisms

A Systematic Review of Consumer-Providers’ Effects on Client Outcomes in Statutory Mental Health Services: The Evidence and the Path Beyond

Suchergebnisse filtern